Granulomatous and suppurative dermatitis at interferon alfa injection sites: Report of 2 cases

Journal of the American Academy of Dermatology

Volumn 46, Issue 4, 2002, Pages 611-616

  Sanders, Scott ^a   Busam, Klaus ^b   Tahan, Steven R ^c   Johnson, Richard A ^d   Sachs, Dana ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CASE REPORT; CELL INFILTRATION; CLINICAL EXAMINATION; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; INJECTION SITE; MALE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SKIN INFLAMMATION; SUPPURATIVE DERMATITIS; THROMBUS; VASCULITIS;

EID: 0036553577     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.119087     Document Type: Article

References (56)

1. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995;33:393-410.
2. Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects associated with interferon alpha therapy: a review. Cutis 1995;56:144.
3. Vial T, Descotes J. Clinical toxicity of interferons. Drug Safety 1994;10:115-50.
4. Montoto S, Bosch F, Estrach T, Blade J, Nomdedeu B, Nontserrat E. Pyoderma gangrenosum triggered by alpha 2b interferon in a patient with chronic granulocytic leukemia. Leuk Lymphoma 1998;30:199-202.
5. Christian MM, Diven DG, Sanchez RL, Soloway RD. Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C. J Am Acad Dermatol 1997;37:118-20.
6. Klapholz L, Ackerstein A, Goldenhersh MA, Vardy D, Nagler A. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT. Bone Marrow Transplant 1993;11:443-6.
7. Detmar U, Agathos M, Nerl C. Allergy of delayed type of recombinant interferon alpha-2C. Contact Dermatitis 1989;20:149-50.
8. Cnudde F, Gharakhanian S, Luboinski J, Dry J, Rozenbaum W. Cutaneous local necrosis following interferon injections [letter]. Int J Dermatol 1991;30:147.
9. Azagury M, Pauwels C, Kornfeld S, Bataille N, Perie G. Severe cutaneous reactions following interferon injections [letter]. Eur J Cancer 1996;32A:1821.
10. Christian B, Derriennic X, Aymard JP. Necrose cutanee locale apres injection d'interferon alpha [letter]. Presse Med 1993;22: 783.
11. Levesque H, Cailleux N, Moore N, Tilly H, Monconduit M, Courtois H. Autoimmune phenomenon associated with cutaneous aseptic necrosis during interferon alpha treatment for chronic myelogenous leukemia [letter]. Br J Dermatol 1995;34: 582-3.
12. Oeda E, Shinohara K. Cutaneous necrosis caused by injection of alpha interferon in a patient with chronic myelogenous leukemia [letter]. Am J Hematol 1993;44:213-4.
13. Orlow SJ, Friedman-Kien AE. Cutaneous ulcerations secondary to interferon alpha therapy in Kaposi's sarcoma [letter]. Arch Dermatol 1992;128:566.
14. Rasokat H, Bendick C, Wemmer U, Steigleder GK. Aseptic skin necrosis after subcutaneous injection of alpha interferon. Dtsch Med Wochenschr 1989;114:458-60.
15. Sparsa A, Loustaud-Ratti V, Liozon E, et al. Cutaneous reactions or necrosis from interferon alpha: can interferon be reintroduced after healing? Six case reports. Rev Med Interne 2000; 21:756-63.
16. Konohana A, Hasegawa Y, Kobayashi T. Cutaneous ulcerations resulting from intramuscular injections of interferon alpha [letter]. J Am Acad Dermatol 1996;35:788-9.
17. Mihara K, Goto T, Shigenaga T. Interferon therapy of C-type chronic hepatitis. Miyazakiikaishi 1993;17:40-4.
18. Nagai A, Nishikiori M, Masuda R. A case of chronic myelogenous leukemia developing cutaneous ulcers during interferon alpha therapy. Int J Hematol 1993;58:129-30.
19. Akiyama Y, Yamada Y, Jidoi J. A case of cutaneous ulcers after intramuscular injections of interferon alpha [abstract]. Jpn J Dermatol 1994;104:436.
20. Tone T, Kawana M, Kinoshita M. Drug eruptions of interferon alpha in patients with C-type hepatitis [abstract]. Jpn J Dermatol 1994;104:1047.
21. Kontochristopoulos G, Stavrinos C, Aroni K, Tassapoulos NC. Cutaneous necrosis by subcutaneous injection of a-interferon in a patient with chronic type B hepatitis [letter]. J Hepatol 1996;25:271.
22. Prussick R, Knowles S, Shear NH. Cutaneous drug reactions. Curr Probl Dermatol 1994;6:81-124.
23. Krainick U, Kantarijan H, Broussard S, Talpaz M. Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res 1998;18:823-7.
24. Sickler JB, Simmons RA, Cobb DK, Sherman KE. Cutaneous necrosis associated with interferon alpha-2b. Am J Gastroenterol 1998;93:463-4.
25. de Ledinghen V, Brudieux E, Beylot-Barry M, Belleannee G, Doutre MS, Couzigou P. Severe local cutaneous necrosis during treatment with interferon-alpha and ribavarin for chronic viral hepatitis C [letter]. Gastroenterol Clin Biol 1997;21:523-4.
26. Virgili A, Corazza M, Lombardi AR, Sighinolfi L. Cutaneous ulcers due to interferon seem not to be related to dosage [letter]. J Eur Acad Dermatol Venereol 1999;13:141-3.
27. Sasseville D, Ghamdi WA, Khenaizan SA. Interferon-induced cutaneous necrosis. J Cutan Med Surg 1999;3:320-3.
28. Okamoto E, Morisaki S, Kitano Y. A case of skin ulceration after subcutaneous injection of IFN-alpha. Skin Res 1995;37:570-2.
29. Matsukura M, Yamada H, Yamashita Y, Tezuka T. Local cutaneous necrosis following interferon-alpha injection. Skin Res 1995;37: 563-9.
30. Stadler R. Interferons in dermatology: present-day standard. Dermatol Clin 1998;16:377-98.
31. Supersaxo A, Hein W, Gallati H, Steffen H. Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res 1988;5:472-6.
32. Gaspari AA. Reply to Konohana [letter]. J Am Acad Dermatol 1996;35:789.
33. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol 1997;37:553-8.
34. Eberlein-Konig B, Hein R, Abeck D, Engst R, Ring J. Cutaneous sarcoid foreign body granulomas developing in sites of previous skin injury after systemic interferon-alpha treatment for chronic hepatitis C [letter]. Br J Dermatol 1999;140:370-2.
35. Stout AJ, Gresser I, Thompson D. Inhibition of wound healing in mice by local interferon a/b injection. Int J Exp Pathol 1993;74: 79-86.
36. Stadler R, Muller R, Orfanos CE. Effect of recombinant alpha A-interferon on DNA synthesis and differentiation of human keratinocytes. Br J Dermatol 1986;1:273-7.
37. Yaar M, Karassik RL, Schnipper LE, Gilchrest BA. Effects of alpha and beta interferons on cultured human keratinocytes. J Invest Dermatol 1985;85:70-4.
38. Tong Y, Tucker SB. Normal mouse skin lymphocyte, Langerhans' cell and keratinocyte responses to intradermal injections of interferon-A and interferon-G. J Interferon Cytokine Res 1995;15:235-41.
39. Tong Y, Tucker SB. Normal human skin lymphocytic and Langerhan's cell responses to intradermal interferon alpha-2B injections. Am J Med Sci 1993;306:23-7.
40. Mozzanica N, Cattaneo A, Boneschi V, Brambilla L, Melotti E, Finzi AF. Immunohistochemical evaluation of basal cell carcinoma during intralesional treatment with alpha-2 interferon. Arch Dermatol Res 1990;282:311-7.
41. Buechner SA. Intralesional interferon alpha-2B in the treatment of basal cell carcinoma. J Am Acad Dermatol 1991;24:731-4.
42. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
43. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteoloytic properties by inhibitors of angiogenesis. J Cell Biochem 1994;55:419-34.
44. Sgonc R, Fuerhapter C, Boeck G, Swerlick R, Fritsch P, Sepp N. Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Allergy Immunol 1998;117:209-14.
45. Zeidman A, Dicker D, Mittelman M. Interferon-induced vasospasm in chronic myelogenous leukemia. Acta Hematol 1998;100:94-6.
46. Durand JM, Quiles N, Kaplanski G, Soubeyard J. Thrombosis and recombinant interferon alpha. Am J Med 1993;95:115-6.
47. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J the Natl Cancer Inst 1989;81:497-501.
48. Cid MC, Hernandez-Rodriguez J, Robert J, del Rio A, Casademont J, Coll-Vincent B, et al. Interferon-a may exacerbate cryoglobulinemia-related ischemic manifestations. Arthritis Rheum 1999;42:1051-5.
49. Magro C, Crowson AN, Mihm M Jr. Cutaneous manifestations of nutritional deficiency states and gastrointestinal disease. In: Elder D, editor. Lever's histopathology of the skin. 8th ed. New York: Lippincott-Raven; 1997. p. 353-68.
50. Hackzel1l-Bradley M, Hedblad MA, Stephansson EA. Metastatic Crohn's disease: report of 3 cases with special reference to histopathologic findings. Arch Dermatol 1996;132:928-32.
51. Sanders S, Tahan SR, Kwan T, Magro CM. Giant cells in pyoderma gangrenosum. J Cutan Pathol 2001;28:97-100.
52. Su WPD, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1996;13:323-30.
53. Delecluse J, de Bast C, Achten G. Pyoderma gangrenosum with altered cellular immunity and dermonecrotic factor. Br J Dermatol 1972;87:529-32.
54. Wakefield AJ, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;2:1057-62.
55. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AFM, More L, Sim R, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991;100:1279-87.
56. Fais S, Capobianchi MR, Silvestri M, Mercuri F, Pallone E, Dianzani F. Interferon expression in Crohn's disease patients: increased interferon-gamma and alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994;14:235-8.